These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 16415689)

  • 1. An evaluation of the efficacy of a cyclosporine-based dry eye therapy when used with marketed artificial tears as supportive therapy in dry eye.
    Sall KN; Cohen SM; Christensen MT; Stein JM
    Eye Contact Lens; 2006 Jan; 32(1):21-6. PubMed ID: 16415689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease.
    Wirta DL; Torkildsen GL; Moreira HR; Lonsdale JD; Ciolino JB; Jentsch G; Beckert M; Ousler GW; Steven P; Krösser S
    Ophthalmology; 2019 Jun; 126(6):792-800. PubMed ID: 30703441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production.
    Pflugfelder SC; De Paiva CS; Villarreal AL; Stern ME
    Cornea; 2008 Jan; 27(1):64-9. PubMed ID: 18245969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of cyclosporine 0.05% ophthalmic emulsion for contact lens-intolerant patients.
    Hom MM
    Eye Contact Lens; 2006 Mar; 32(2):109-11. PubMed ID: 16538135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial.
    Chen M; Gong L; Sun X; Xie H; Zhang Y; Zou L; Qu J; Li Y; He J
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):361-6. PubMed ID: 20698799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Clinical Efficacy and Safety of a Novel Cyclosporin A Nanoemulsion in the Treatment of Dry Eye Syndrome.
    Kim HS; Kim TI; Kim JH; Yoon KC; Hyon JY; Shin KU; Choi CY
    J Ocul Pharmacol Ther; 2017 Sep; 33(7):530-538. PubMed ID: 28759302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversibility of dry eye deceleration after topical cyclosporine 0.05% withdrawal.
    Rao SN
    J Ocul Pharmacol Ther; 2011 Dec; 27(6):603-9. PubMed ID: 21999340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of tear film breakup time extension and ocular protection index scores among three marketed lubricant eye drops.
    Ousler GW; Michaelson C; Christensen MT
    Cornea; 2007 Sep; 26(8):949-52. PubMed ID: 17721294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of lubricating agents with different osmolalities on tear osmolarity and other tear function tests in patients with dry eye.
    Cömez AT; Tufan HA; Kocabıyık O; Gencer B
    Curr Eye Res; 2013 Nov; 38(11):1095-103. PubMed ID: 23841565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1 year of twice-daily therapy.
    Su MY; Perry HD; Barsam A; Perry AR; Donnenfeld ED; Wittpenn JR; D'Aversa G
    Cornea; 2011 Oct; 30(10):1098-104. PubMed ID: 21407074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of cyclosporine 0.05% ophthalmic emulsion in contact lens wearers with dry eyes.
    Willen CM; McGwin G; Liu B; Owsley C; Rosenstiel C
    Eye Contact Lens; 2008 Jan; 34(1):43-5. PubMed ID: 18180683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of topical cyclosporine a plus artificial tears versus artificial tears treatment on conjunctival goblet cell density in dysfunctional tear syndrome.
    Demiryay E; Yaylali V; Cetin EN; Yildirim C
    Eye Contact Lens; 2011 Sep; 37(5):312-5. PubMed ID: 21792057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.
    Sall K; Stevenson OD; Mundorf TK; Reis BL
    Ophthalmology; 2000 Apr; 107(4):631-9. PubMed ID: 10768324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.
    Barber LD; Pflugfelder SC; Tauber J; Foulks GN
    Ophthalmology; 2005 Oct; 112(10):1790-4. PubMed ID: 16102833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical cyclosporine 0.05% for the prevention of dry eye disease progression.
    Rao SN
    J Ocul Pharmacol Ther; 2010 Apr; 26(2):157-64. PubMed ID: 20415623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusis.
    Salib GM; McDonald MB; Smolek M
    J Cataract Refract Surg; 2006 May; 32(5):772-8. PubMed ID: 16765793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy.
    Toker E; Asfuroğlu E
    Cornea; 2010 Feb; 29(2):133-40. PubMed ID: 19966564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, Safety, and Tolerability of a Novel Cyclosporine, a Formulation for Dry Eye Disease: A Multicenter Phase II Clinical Study.
    Peng WY; Chen RX; Dai H; Zhu L; Li Y; Gao ZQ; Li XY; Zhou SY
    Clin Ther; 2021 Mar; 43(3):613-628. PubMed ID: 33546885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%.
    Sheppard JD; Donnenfeld ED; Holland EJ; Slonim CB; Solomon R; Solomon KD; McDonald MB; Perry HD; Lane SS; Pflugfelder SC; Samudre SS
    Eye Contact Lens; 2014 Sep; 40(5):289-96. PubMed ID: 25083776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Slitlamp biomicroscopy of the tear film of patients using topical Restasis and Refresh Endura.
    Solomon R; Perry HD; Donnenfeld ED; Greenman HE
    J Cataract Refract Surg; 2005 Apr; 31(4):661-3. PubMed ID: 15899439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.